Rajiv Vakani Emerging Therapies Studio wall
← Studio wall
Open file Thinking artifact v0.1 frozen Last touched Jul 2026

Awaiting NCT07437547 results · any serious human efficacy package

Watching compounding / WADA wording · product identity claims

Open until human evidence catches the conversation

BPC-157

Investigation

How do we evaluate a therapy
when enthusiasm outpaces
human evidence?

Understanding what kinds of evidence exist and what kinds do not. Not dismissive. Not promotional.

Investigation

What is being claimed?

“Wolverine peptide,” miraculous soft-tissue repair, oral for gut / injection for joints, “safe because natural,” stacks with TB-500. Forums treat scarce published harms as proof of safety.

Investigation

What the landscape contains

Abundant: preclinical literature across tendon, ligament, muscle, wound, GI, vascular models. Mechanistic themes explain why enthusiasm is not random.

Thin: human clinical evidence for popular recovery claims. No completed published randomized placebo-controlled efficacy trials identified for those uses. Commonly cited human reports are small uncontrolled pilots. Sports-medicine reviews keep finding preclinical majority vs minimal clinical inclusion.

Not yet: NCT07437547, a recruiting Phase 2 RCT for grade II hamstring strain. The question is becoming properly askable. It is not answered.

Outside journals, still real: not FDA-approved; compounding contested; WADA prohibition; product identity/purity concerns in gray channels.

Investigation

What we should conclude today

  • Interesting preclinical signal. Not imaginary.
  • Not clinically established for the recovery indications dominating patient conversation.
  • Absence of published RCTs is the central clinical fact.
  • Tiny pilots cannot carry forum certainty.
  • Human safety is incompletely characterized at approved-drug standards.
  • Use can be common while evidence is immature.
  • Watch serious trials. Update when the landscape changes.

Neither “rodents healed, so it works” nor “uncertain, so anyone using it is foolish” fits the evidence shape.

Still open

  • Does NCT07437547 move anything?
  • Does a real human package show up before the forums harden further?
  • How blunt should we be about product identity?

Investigation

Why should an RD care?

You will rarely “prescribe BPC-157.” You will meet people already using or considering it while a tendon stalls.

Evidence-anchored work still exists: energy availability, protein, sleep, alcohol, graded loading with rehab. Under-fueling and early return-to-play sabotage healing more reliably than any unapproved peptide has been shown to rescue it.

Translate categories without condescension. Keep rehab in the room. Ask about source. Separate stacks. Name anti-doping early. Respect hope without inflating evidence.

Usable line: “There is a substantial animal research story and very little high-quality human trial evidence for the recovery uses people talk about. It isn’t FDA-approved, and tested athletes generally can’t use it. What we can do well together is protect your healing environment: fuel, protein, sleep, and rehab.”

Current thinking

as of July 2026 · subject to revision

BPC-157 is an unapproved peptide with a large preclinical literature and a currently thin human clinical package for the claims that drive patient interest. Public and clinic enthusiasm run ahead of that package. Access, anti-doping rules, and product quality shape real-world risk as much as mechanism slides do. A usable stance today is curious, precise, and unfinished.

Evidence consulted Open file

Evidence consulted while building this notebook. Not a citation for every sentence.

Primary

  • Preclinical BPC-157 literature (tendon, muscle, GI, vascular models; as mapped in landscape)
  • Human non-RCT pilots / series cited in landscape (uncontrolled; thin package)
  • NCT07437547 · Phase 2 hamstring RCT · recruiting (no results at notebook date)
  • NCT02637284 · historic Phase 1 · Unknown status on ClinicalTrials.gov; results submitted then withdrawn; no published package

Regulatory

  • FDA PCAC briefing materials · BPC-157 · Jul 2026 cycle (staff against 503A Bulks List inclusion)
  • WADA prohibited-list framing for BPC-157
  • ClinicalTrials.gov · NCT07437547

Secondary

  • Sports-medicine / translational reviews on preclinical–clinical gap

Freeze trail · Jul 2026. Landscape and artifact drew on these. News and forums stayed in research notes only.

Frozen thinking artifact v0.1 · Jul 2026. Not medical advice.